The purpose of the present invention is to provide a novel compound having ACC2 inhibition activity and to provide a pharmaceutical composition containing the compound. Provided are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. (In formula (I), R1 represents a substituted or unsubstituted fused aromatic heterocyclic group represented by formula (II) (in formula (II), ring B represents a 5-membered ring and ring C represents a 6-membered ring), ring A represents a substituted or unsubstituted nonaromatic carbocyclic ring or the like, -L1- represents -O-(CR6R7)m- or the like, -L2- represents -O-(CR6R7)n- or the like, each R6 independently represents hydrogen or the like, each R7 independently represents hydrogen or the like, each m independently represents an integer of 0, 1, 2, or 3, each n independently represents an integer of 1, 2, or 3, R2 represents a substituted or unsubstituted alkyl, R3 represents hydrogen or a substituted or unsubstituted alkyl, and R4 represents a substituted or unsubstituted alkyl carbonyl or the like).La presente invención se refiere a compuestos con actividad inhibidora selectiva de ACC2. Además, una composición farmacéutica que comprende el compuesto. Un compuesto de la fórmula: (ver Fórmula) o su sal farmacéuticamente aceptable, en donde R1 es heterociclilo aromático fusionado sustituido o no sustituido representado por la fórmula: (ver Fórmula) en donde el anillo B es anillo de 5 elementos, anillo C es anillo de 6 elementos； el anillo A es carbociclo no aromático sustituido o no sustituido, o similares； -L1- es -O-(CR6R7)m-, o similares； -L2- es -O-(CR6R7)n-, o similares； cada R6 es, de modo independiente, hidrógeno, o similares； cada R7 es, de modo independiente, hidrógeno, o similares； cada m es, de modo independiente, un número entero de 0, 1, 2 ó 3； cada n es, de modo independiente, un número entero de 1, 2 ó 3； R2 es alquilo sustituido o no sustituido； R3 es hidrógeno o alquilo sustituido o
